PREVIOUS
✖
R21/Matrix M
May 8 , 2021
1292 days
864
0
- R21/Matrix M has been developed by scientists at University of Oxford.
- This malaria vaccine candidate has shown promise in phase 2b clinical trials, with high efficacy at 77%.
- The new vaccine candidate, called R21/Matrix M, is a modified version of RTS,S.
- This vaccine is designed to stop the Plasmodium falciparum malaria parasite from entering the liver and preventing the subsequent deadly blood stages.
Leave a Reply
Your Comment is awaiting moderation.